PharmaShots | Incisive News in 3 Shots

Subscribe Now

Less Frequent

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Cancer

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Can...

August 18, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us